Stockscreener 앱 받기
2.80
3.70%
0.10
시간 외 거래:
2.88
0.08
+2.86%
전일 마감가:
$2.70
열려 있는:
$2.69
하루 거래량:
331.23K
Relative Volume:
1.91
시가총액:
$14.94M
수익:
-
순이익/손실:
$-30.33M
주가수익비율:
-0.0999
EPS:
-28.0369
순현금흐름:
$-24.28M
1주 성능:
+12.00%
1개월 성능:
+32.70%
6개월 성능:
-32.37%
1년 성능:
-83.18%
1일 변동 폭
$2.672
$2.8998
1주일 범위
$2.5079
$2.8998
52주 변동 폭
$1.79
$24.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.80 | 14.46M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech (MBRX) Sees Modest Uptick as Stock Consolidates Near SupportVWAP Bounce - newsline.com
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
Moleculin Biotech Announces Positive Market Assessment for Annamycin in Relapsed/Refractory AML (R/R AML) – Key Clinical Advantages and Unmet Needs Highlighted - Minichart
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy - TipRanks
Moleculin Biotech Reports Strong Physician Interest in Annamycin for R/R AML Treatment, Highlighting Unmet Needs and Positive Market Assessment - Quiver Quantitative
Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML - TradingView
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML - The Manila Times
Strong physician interest in Annamycin reported by Moleculin (NASDAQ: MBRX) - Stock Titan
Leukemia drug Annamycin wins doctor and insurer support in new survey - Stock Titan
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor What This Means Segment - marketscreener.com
Moleculin Biotech (MBRX) Holds Steady at $2.46 – Key Levels in FocusOvervalued Signals - newsline.com
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor 'What This Means” Segment - The Manila Times
Leukemia trial of Annamycin hits 45-patient milestone, mid‑2026 data ahead - Stock Titan
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment - Yahoo Finance
Moleculin Biotech (MBRX) Holds Near Key Support as Modest Uptick Signals Cautious TradingTrend Following Picks - The Legal Advocate
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO - TipRanks
Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure - TradingView
Moleculin Biotech (MBRX) shares ASCO data on Annamycin cardiac safety and MIRACLE trial - Stock Titan
Moleculin Presents ASCO 2026 Data Demonstrating No - GlobeNewswire
Moleculin Biotech (MBRX) Edges Higher on Modest Volume: Support Holds Near $2.65Early Entry Signals - newsline.com
Moleculin Biotech (MBRX) Holds Steady at $2.73 Amid Consolidation PhaseHigh Reward Trades - newsline.com
Moleculin Biotech (MBRX) Rises 3.27%: Breaking Above Support with Resistance in SightPCR Spike - thelegaladvocate.com
Moleculin Biotech’s MIRACLE Trial Data Exceeds Historical Benchmarks for AML Treatment - geneonline.com
Moleculin Biotech Releases Updated Investor Information Presentation - TipRanks
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech | 8-K: Current report - Moomoo
Moleculin Biotech (MBRX) Holds Steady at $2.39 as Trading Remains FlatVOLD Alert - newsline.com
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - The Manila Times
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Moleculin Biotech, Inc. Presents Cardiac Safety Data for Annamycin at 2026 ASCO Annual Meeting - Quiver Quantitative
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Why did MBRX stock climb 14% today? - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech Q1 net loss widens as R&D costs rise - TradingView
Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative
MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Moleculin Biotech Inc 주식 (MBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
2.60%
0.94%
자본화:
|
볼륨(24시간):